Cargando…

Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice

BACKGROUND: The dual-loaded nano-delivery system can realize chemotherapeutic drug and small interfering RNA (siRNA) co-loading as well as enhance the therapeutic effect of drugs on tumors through a synergistic effect, while reducing their toxic and side effects on normal tissues. METHODS: Previousl...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Mingji, Hou, Yan, Quan, Xiuquan, Chen, Liqing, Gao, Zhonggao, Huang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370882/
https://www.ncbi.nlm.nih.gov/pubmed/34413645
http://dx.doi.org/10.2147/IJN.S313339
_version_ 1783739524916969472
author Jin, Mingji
Hou, Yan
Quan, Xiuquan
Chen, Liqing
Gao, Zhonggao
Huang, Wei
author_facet Jin, Mingji
Hou, Yan
Quan, Xiuquan
Chen, Liqing
Gao, Zhonggao
Huang, Wei
author_sort Jin, Mingji
collection PubMed
description BACKGROUND: The dual-loaded nano-delivery system can realize chemotherapeutic drug and small interfering RNA (siRNA) co-loading as well as enhance the therapeutic effect of drugs on tumors through a synergistic effect, while reducing their toxic and side effects on normal tissues. METHODS: Previously, we developed layered smart nanoparticles (NPs) to co-deliver survivin siRNA as well as small molecule drugs for lung cancer. In this study, we used such smart NPs to co-deliver paclitaxel (PTX) and siRNA against vascular endothelial growth factor (VEGF) gene for breast cancer therapy in mice models. For the prepared NPs, characterizations such as particle size, zeta potential, gel electrophoresis imaging and in vitro stability were investigated. Then, 4T1 cells were used to evaluate the in vitro VEGF silencing capacity, tumor cell inhibitory and anti-apoptotic abilities. Finally, an orthotopic model of mouse breast cancer was established to evaluate the in vivo antitumor effects and safety properties of PTX-siRNA(VEGF)-NPs. RESULTS: We prepared PTX-siRNA(VEGF)-NPs with particle size of 85.25 nm, PDI of 0.261, and zeta potential of 5.25 mV. The NPs with VEGF siRNA effectively knocked down the expression of VEGF mRNA. Cell counting kit-8 (CCK-8) and apoptosis assays revealed that the PTX-siRNA(VEGF)-NPs exhibited antiproliferation effect of PTX on 4T1 cells. The in vivo anti-tumor study indicated that PTX-siRNA(VEGF)-NPs could exert an antitumor effect by inhibiting the formation and development of new blood vessels in tumor tissues, thereby cutting off nutrient and blood supplies required for tumor tissue growth. Both the anti-tumor efficacy and in vivo safety of the PTX-siRNA(VEGF)-NPs group were better than that of the PTX-NPs and siRNA(VEGF)-NPs groups. CONCLUSION: The combination of PTX and VEGF siRNA exerts good antitumor effect on 4T1 tumor cells. This study provides a theoretical and practical basis for breast cancer therapy.
format Online
Article
Text
id pubmed-8370882
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-83708822021-08-18 Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice Jin, Mingji Hou, Yan Quan, Xiuquan Chen, Liqing Gao, Zhonggao Huang, Wei Int J Nanomedicine Original Research BACKGROUND: The dual-loaded nano-delivery system can realize chemotherapeutic drug and small interfering RNA (siRNA) co-loading as well as enhance the therapeutic effect of drugs on tumors through a synergistic effect, while reducing their toxic and side effects on normal tissues. METHODS: Previously, we developed layered smart nanoparticles (NPs) to co-deliver survivin siRNA as well as small molecule drugs for lung cancer. In this study, we used such smart NPs to co-deliver paclitaxel (PTX) and siRNA against vascular endothelial growth factor (VEGF) gene for breast cancer therapy in mice models. For the prepared NPs, characterizations such as particle size, zeta potential, gel electrophoresis imaging and in vitro stability were investigated. Then, 4T1 cells were used to evaluate the in vitro VEGF silencing capacity, tumor cell inhibitory and anti-apoptotic abilities. Finally, an orthotopic model of mouse breast cancer was established to evaluate the in vivo antitumor effects and safety properties of PTX-siRNA(VEGF)-NPs. RESULTS: We prepared PTX-siRNA(VEGF)-NPs with particle size of 85.25 nm, PDI of 0.261, and zeta potential of 5.25 mV. The NPs with VEGF siRNA effectively knocked down the expression of VEGF mRNA. Cell counting kit-8 (CCK-8) and apoptosis assays revealed that the PTX-siRNA(VEGF)-NPs exhibited antiproliferation effect of PTX on 4T1 cells. The in vivo anti-tumor study indicated that PTX-siRNA(VEGF)-NPs could exert an antitumor effect by inhibiting the formation and development of new blood vessels in tumor tissues, thereby cutting off nutrient and blood supplies required for tumor tissue growth. Both the anti-tumor efficacy and in vivo safety of the PTX-siRNA(VEGF)-NPs group were better than that of the PTX-NPs and siRNA(VEGF)-NPs groups. CONCLUSION: The combination of PTX and VEGF siRNA exerts good antitumor effect on 4T1 tumor cells. This study provides a theoretical and practical basis for breast cancer therapy. Dove 2021-08-13 /pmc/articles/PMC8370882/ /pubmed/34413645 http://dx.doi.org/10.2147/IJN.S313339 Text en © 2021 Jin et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Jin, Mingji
Hou, Yan
Quan, Xiuquan
Chen, Liqing
Gao, Zhonggao
Huang, Wei
Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice
title Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice
title_full Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice
title_fullStr Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice
title_full_unstemmed Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice
title_short Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice
title_sort smart polymeric nanoparticles with ph-responsive and peg-detachable properties (ii): co-delivery of paclitaxel and vegf sirna for synergistic breast cancer therapy in mice
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370882/
https://www.ncbi.nlm.nih.gov/pubmed/34413645
http://dx.doi.org/10.2147/IJN.S313339
work_keys_str_mv AT jinmingji smartpolymericnanoparticleswithphresponsiveandpegdetachablepropertiesiicodeliveryofpaclitaxelandvegfsirnaforsynergisticbreastcancertherapyinmice
AT houyan smartpolymericnanoparticleswithphresponsiveandpegdetachablepropertiesiicodeliveryofpaclitaxelandvegfsirnaforsynergisticbreastcancertherapyinmice
AT quanxiuquan smartpolymericnanoparticleswithphresponsiveandpegdetachablepropertiesiicodeliveryofpaclitaxelandvegfsirnaforsynergisticbreastcancertherapyinmice
AT chenliqing smartpolymericnanoparticleswithphresponsiveandpegdetachablepropertiesiicodeliveryofpaclitaxelandvegfsirnaforsynergisticbreastcancertherapyinmice
AT gaozhonggao smartpolymericnanoparticleswithphresponsiveandpegdetachablepropertiesiicodeliveryofpaclitaxelandvegfsirnaforsynergisticbreastcancertherapyinmice
AT huangwei smartpolymericnanoparticleswithphresponsiveandpegdetachablepropertiesiicodeliveryofpaclitaxelandvegfsirnaforsynergisticbreastcancertherapyinmice